BACKGROUND: Plasmodium falciparum-infected erythrocytes adhere to chondroitin sulfate A (CSA) to sequester in the human placenta, and pregnancy malaria (PM) is associated with the development of disease in and the death of both mother and child. A PM vaccine appears to be feasible, because women become protected as they develop antibodies against placental infected erythrocytes (IEs). Two IE surface molecules, VAR1CSA and VAR2CSA, bind CSA in vitro and are potential vaccine candidates. METHODS: We expressed all domains of VAR1CSA and VAR2CSA as mammalian cell surface proteins, using a novel approach that allows rapid purification, immobilization, and quantification of target antigen. For serum samples from East Africa, we measured reactivity to all domains, and we examined the effects of host sex and parity, as well as the effects of parasite antigenic variation. RESULTS: Serum samples obtained from multigravid women had a higher reactivity to all VAR2CSA domains than did those obtained from primigravid women or from men. Conversely, serum samples obtained from men had consistently higher reactivity to VAR1CSA domains than did those obtained from gravid women. Seroreactivity was strongly influenced by antigenic variation of VAR2CSA Duffy binding-like domains. CONCLUSIONS: Women acquire antibodies to VAR2CSA over successive pregnancies, but they lose reactivity to VAR1CSA. Serum reactivity to VAR2CSA is variant specific, and future studies should examine the degree to which functional antibodies, such as binding-inhibition antibodies, are variant specific.
BACKGROUND: Plasmodium falciparum-infected erythrocytes adhere to chondroitin sulfate A (CSA) to sequester in the human placenta, and pregnancy malaria (PM) is associated with the development of disease in and the death of both mother and child. A PM vaccine appears to be feasible, because women become protected as they develop antibodies against placental infected erythrocytes (IEs). Two IE surface molecules, VAR1CSA and VAR2CSA, bind CSA in vitro and are potential vaccine candidates. METHODS: We expressed all domains of VAR1CSA and VAR2CSA as mammalian cell surface proteins, using a novel approach that allows rapid purification, immobilization, and quantification of target antigen. For serum samples from East Africa, we measured reactivity to all domains, and we examined the effects of host sex and parity, as well as the effects of parasite antigenic variation. RESULTS: Serum samples obtained from multigravid women had a higher reactivity to all VAR2CSA domains than did those obtained from primigravid women or from men. Conversely, serum samples obtained from men had consistently higher reactivity to VAR1CSA domains than did those obtained from gravid women. Seroreactivity was strongly influenced by antigenic variation of VAR2CSA Duffy binding-like domains. CONCLUSIONS:Women acquire antibodies to VAR2CSA over successive pregnancies, but they lose reactivity to VAR1CSA. Serum reactivity to VAR2CSA is variant specific, and future studies should examine the degree to which functional antibodies, such as binding-inhibition antibodies, are variant specific.
Authors: Harold Obiakor; Marion Avril; Nicholas J Macdonald; Prakash Srinivasan; Karine Reiter; Charles Anderson; Kevin L Holmes; Michal Fried; Patrick E Duffy; Joseph D Smith; David L Narum; Louis H Miller Journal: Clin Vaccine Immunol Date: 2013-01-23
Authors: Yukie M Lloyd; Rui Fang; Naveen Bobbili; Koko Vanda; Elise Ngati; Maria J Sanchez-Quintero; Ali Salanti; John J Chen; Rose G F Leke; Diane W Taylor Journal: Infect Immun Date: 2018-08-22 Impact factor: 3.441
Authors: Marion Avril; Marianne J Hathaway; Megan M Cartwright; Severin O Gose; David L Narum; Joseph D Smith Journal: Malar J Date: 2009-06-29 Impact factor: 2.979
Authors: Michal Fried; Marion Avril; Richa Chaturvedi; Pablo Fernandez; Joseph Lograsso; David Narum; Morten A Nielsen; Andrew V Oleinikov; Mafalda Resende; Ali Salanti; Tracy Saveria; Kathryn Williamson; Alassane Dicko; Artur Scherf; Joseph D Smith; Thor G Theander; Patrick E Duffy Journal: Infect Immun Date: 2012-12-03 Impact factor: 3.441
Authors: Andrew V Oleinikov; Emily Amos; Isaac Tyler Frye; Eddie Rossnagle; Theonest K Mutabingwa; Michal Fried; Patrick E Duffy Journal: PLoS Pathog Date: 2009-04-17 Impact factor: 6.823